Breaking News, Collaborations & Alliances

Pfizer & BioNTech to Develop mRNA-Based Shingles Vaccine

Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology.

Author Image

By: Charlie Sternberg

Associate Editor

Pfizer Inc. and BioNTech SE have announced a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles (herpes zoster virus, or HZV), a disease that impacts about one in three people in the United States during their lifetime.   The collaboration builds on the companies’ success in developing the first approved and most widely used mRNA vaccine to help prevent COVID-19. This is the third collaboration between Pfiz...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters